HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Current principles in the chemoprophylaxis of acute respiratory viral infections].

AbstractAIM:
To evaluate the preventive efficacy of the Russian antiviral drug ingavirin (vitaglutam) in the epidemiological foci with the peak incidence of acute respiratory viral infections (ARVI).
SUBJECTS AND METHODS:
Four hundred men and women aged 18 to 65 years from the epidemic foci of ARVI who had been in close daily contact with the patients whose diagnosis was verified by laboratory tests were examined. Two hundred persons received prophylaxis with ingavirin (a 90-mg oral capsule once daily for 7 days) and 200 took placebo according to the same scheme. The efficiency index and coefficient were calculated and the relative risk of the disease was estimated to evaluate the efficiency of ARVI prevention. A pharmacoeconomic analysis was made.
RESULTS:
There is evidence that the administration of 90-mg ingavirin capsules (OAO "Valenta Farm", Russia) caused a reduction in morbidity rates among those who had been in contact by 63% and in the risk of ARVI by 2.7 times. There was a reduction in the duration of fever by one day and a milder course of respiratory disease in the ingavirin-treated contact persons who developed ARVI.
CONCLUSION:
Ingavirin meets all requirements for current drugs for the nonspecific prevention of ARVI at the peak of its incidence. It has a pronounced protective effect and broad-spectrum activity, low toxicity and high safety, which allows it to be recommended for the emergency intrafocal prevention at the peak of the incidence of influenza and ARVI in adults.
AuthorsA A Shul'diakov, E P Liapina, V I Kuznetsov
JournalTerapevticheskii arkhiv (Ter Arkh) Vol. 85 Issue 11 Pg. 27-33 ( 2013) ISSN: 0040-3660 [Print] Russia (Federation)
PMID24432596 (Publication Type: Comparative Study, English Abstract, Journal Article, Multicenter Study)
Chemical References
  • Antiviral Agents
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents (therapeutic use)
  • Chemoprevention (methods, standards)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Morbidity (trends)
  • Practice Guidelines as Topic
  • Respiratory Tract Infections (epidemiology, prevention & control, virology)
  • Russia (epidemiology)
  • Virus Diseases (epidemiology, prevention & control)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: